Riskpilot← Back to searchSign inGet full access21st.BIO A/S
A/SActiveCVR 41554908Sydmarken 42Engineering activities and related technical consultancy · NACE 7112Est. 202042 employees21st.bio
Revenue 2024
DKK -17,2M
+75% vs 2023
EBITDA margin
267.3%
-53% vs 2023
Equity ratio
74.9%
Financial strength
Net profit 2024
DKK -41,7M
+1% vs 2023
| Revenue | DKK -17,2M | +75% |
| EBITDA | DKK -46M | -53% |
| Net profit | DKK -41,7M | +1% |
| Total assets | DKK 440,9M | +5% |
| Equity | DKK 330,3M | +12% |
| Employees | 42 | — |
Legal name
21st.BIO A/S
CVR number
41554908
Legal form
Aktieselskab
NACE code
7112 · Engineering activities and related technical consultancy
Founded
1. august 2020
Share capital
DKK 16.700.348
Employees
42 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsesformanden i forening med et bestyrelsesmedlem , eller af bestyrelsesformanden i forening med en direktør eller af den samlede bestyrelse.
Company purpose
Selskabets formål er rådgivning om, investering i og udvikling af industrielle biotech-løsninger samt aktiviteter, der efter bestyrelsens skøn er forbundet dermed.
Address
Sydmarken 42
Email
info@21st.bio
Website
21st.bio
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | -19.455 | -21.931 | -9.826 | -17.203 |
| Staff expenses | -2.808 | -16.445 | -20.174 | -28.774 |
| EBITDA | -22.264 | -38.376 | -29.999 | -45.977 |
| Depreciation & amort. | -0 | -17.071 | -18.068 | -20.008 |
| EBIT | -22.264 | -55.447 | -48.068 | -65.984 |
| Net financials | 468 | 1.238 | -400 | 5.058 |
| Profit before tax | -21.796 | -54.209 | -48.468 | -60.926 |
| Tax | -0 | -17.596 | -6.208 | -19.266 |
| Net profit | -21.796 | -36.612 | -42.260 | -41.660 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 33.964 | 329.388 | 419.200 | 440.894 |
| Equity | 23.854 | 262.616 | 294.809 | 330.332 |
| Long-term debt | 0 | 0 | 46.536 | 45.105 |
| Short-term debt | 10.110 | 12.587 | 22.341 | 13.410 |
| Total debt | 10.110 | 12.587 | 68.877 | 58.515 |
EBITDA margin
-4597682600.0%
This company
15.8%
Market median
-29099257062% vs market
20212024
Equity ratio
74.9%
This company
38.2%
Market median
+96% vs market
20212024
Return on equity
-12.6%
This company
18.4%
Market median
-168% vs market
20212024
Net profit margin
-4166012300.0%
This company
8.1%
Market median
-51432250717% vs market
20212024
Asset turnover
-0.04×
This company
1.12×
Market median
-104% vs market
20212024
Debt / equity
0.33×
This company
0.62×
Market median
+47% vs market
20212024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2020-08-01 – 2021-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TU Management | Management | 2022 | — | — |
TG Management | Management | 2020 | — | — |
PF Management | Management | 2022 | — | — |
TT Management | Management | 2021 | — | — |
JA Management | Management | 2025 | — | — |
HM Management | Management | 2025 | — | — |
MB Management | Management | 2023 | — | — |
SR Founder | Founder | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2023 | — | — | |
| Chairman | 2025 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Novo Holdings A/S | Company | 33.3% | 33.3% | 2024 |
NOVOZYMES A/S | Company | 33.3% | 33.3% | 2022 |
Momentum Techinvest ApS | Company | 5.0% | 5.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NOVO NORDISK FONDEN
21st.BIO A/S Board members of 21st.BIO A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Thorvald Uhrskov Ullum | Management | 0 companies |
| Thomas Günther Schmidt | Management | 0 companies |
| Per Falholt | Management | 0 companies |
| Thomas Troelsgaard Kabel | Management | 0 companies |
| Jose Arnau Martinez | Management | 0 companies |
| Henrik Marcus Geertz-Hansen | Management | 0 companies |
| Mikael Bechsgaard | Management | 0 companies |
| Steen Riisgaard | Founder | 0 companies |
| Thomas Grotkjær | Board of Directors | 0 companies |
| Anders Bendsen Spohr | Chairman | 0 companies |
| Niels Jørgen Kornerup | Board of Directors | 0 companies |
| Thomas Dal Stenfeldt Batchelor | Board of Directors | 0 companies |
| Claus Crone Fuglsang | Board of Directors | 0 companies |
| Søren Møller | Chairman | 0 companies |
| Amy Louise Byrick | Board of Directors | 0 companies |